Cantor Fitzgerald
Cantor Fitzgerald is a leading brokerage service for Wall Street's fixed income inter-dealer community. Cantor is a recognized leader in the specialized areas of equity and fixed income capital markets, offering an impressive array of products and services to more than 5000 institutional clients around the world.
Cantor suffered a devastating loss on September 11, 2001, when the World Trade Center terrorist attacks claimed the lives of 658 of the company's 960 New York-based employees.
Howard W. Lutnick is the company's Chairman and CEO.
View Older Stories View More Recent Stories
-
Tango Therapeutics raises $225 million in stock offering
-
Tango Therapeutics Announces $225 Million Financing
-
Fossil extends exchange offer deadline after falling short of minimum threshold
-
Fossil extends exchange offer for senior notes after missing 90% threshold
-
Fossil Announces Intention to Proceed with the UK Proceeding and Extension of Exchange Offer for Its Senior Notes
-
Electra secures $82 million to fund North America's first cobalt refinery
-
Electra Completes Financing and Debt Restructuring, Fully Funding North America’s First Cobalt Sulfate Refinery
-
Cantor Fitzgerald Reiterates Elevance (ELV) at Overweight: Cautious of '26 Medicaid Environment
-
Cantor Fitzgerald Reiterates Chubb Corporation (CB) at Neutral; Notes Group in Strong Relative Place
-
Cantor Fitzgerald Raises CACI International (CACI) PT to $675 Ahead of F1Q26 Earnings
-
Cantor Fitzgerald Reiterates Texas Instruments (TXN) at Neutral After 3Q Beat, 4Q Guidance Miss
-
Cantor Fitzgerald Reiterates Ardelyx, Inc (ARDX) at Overweight on Expected Ibsrela Upside
-
Cantor Fitzgerald Reiterates Alnylam Pharmaceuticals (ALNY) at Neutral on Good Execution
-
Cantor Fitzgerald Reiterates Fortinet (FTNT) at Neutral: Investment Stance Unchanged into 3Q25
-
Cantor Fitzgerald Reiterates Checkpoint Software (CHKP) at Neutral; Constructive on Long-Term Outlook
-
Tesla set for strong quarter fueled by rush to get expiring US EV tax credits
-
Cantor Fitzgerald Downgrades Alector Inc. (ALEC) to Neutral
-
Cantor Fitzgerald Reiterates Cytokinetics (CYTK) at Overweight Post Model Update
-
Cantor Fitzgerald Starts Nuscale Power (SMR) at Overweight, 'Only NRC-Approved Advanced Nuclear Player'
-
Cantor Fitzgerald Reiterates Overweight Rating on W.R. Berkley (WRB) Ahead of Q3 Earnings
-
Cantor Fitzgerald Reiterates Overweight Rating on Tesla (TSLA) Ahead of Q3 Earnings
-
Cantor Fitzgerald Starts Sui Group (SUIG) at Overweight
-
Cantor Fitzgerald Starts Kyivstar Group (KYIV) at Overweight
-
Form 13F-HR CANTOR FITZGERALD INVEST For: Sep 30
-
Disc Medicine prices $250 million stock offering at $84 per share
-
Disc Medicine Announces Pricing of $250 Million Upsized Public Offering of Common Stock and Pre-Funded Warrants
-
Lexeo Therapeutics closes $153.8 million public offering and private placement
-
Lexeo Therapeutics Announces Closing of Public Offering and Concurrent Private Placement and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares in the Public Offering
-
Investor behind Zions, Western Alliance bad loans is tied to $270 million in troubled debt
-
Cantor Fitzgerald Reiterates Overweight Rating on Microsoft (MSFT) as Windows 10 Support Ends
-
Cantor Fitzgerald Starts Kodiak AI (KDK) at Overweight
-
Regan Total Return Income Fund (RCIRX) Celebrates Five-Year Anniversary
-
Cantor Fitzgerald Reiterates Overweight Rating on Varonis Systems (VRNS) After AI Identity Protection Launch
-
Cantor Fitzgerald Reiterates Overweight Rating on GitLab Inc (GTLB) Amid Acquisition Speculation
-
Cantor Fitzgerald Reiterates Overweight Rating on Verastem (VSTM) on Dual-Program Growth Potential
-
Cantor Fitzgerald Reiterates Overweight Rating on Summit Therapeutics plc (SMMT) After Management Meet
-
Disc Medicine announces $220M public stock offering
-
Disc Medicine Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
-
ACG METALS LIMITED: Q3 2025 YTD Operations and Capital Structure Update
-
Freddie Mac Announces Results of Tender Offer for Certain STACR Notes
-
Cantor Fitzgerald Reiterates Overweight Rating on Zevra Therapeutics, Inc. (ZVRA): Notes Patent Potential
-
Cantor Fitzgerald Reiterates Overweight Rating on Artiva Biotherapeutics (ARTV) on NK Therapy Progress
-
Cantor Fitzgerald Reiterates Overweight Rating on Taysha Gene Therapies (TSHA): Says it's Undervalued
-
Cantor Fitzgerald Reiterates Overweight Rating on Eli Lilly (LLY) Amid GLP-1 Pricing Uncertainty
-
Cantor Fitzgerald Reiterates Overweight Rating on Esperion Therapeutics (ESPR): Says Expenses Manageable
-
Cantor Fitzgerald Reiterates Overweight Rating on Oracle (ORCL): Notes Strong AI Pipeline, OCI Growth
-
Disc Medicine (IRON) PT Raised to $153 at Cantor Fitzgerald After FDA Priority Voucher Win
-
Planet Labs (PL) PT Raised to $20 at Cantor Fitzgerald on Sales Growth, Margin Outlook
-
Lexeo Therapeutics prices $135 million public offering at $8 per share
-
Lexeo Therapeutics Announces Pricing of Public Offering and Concurrent Private Placement

